Concert’s initial alopecia data fall short against Pfizer, prompting investor blow back
An interim analysis of mid-stage data on Concert Pharmaceuticals’ $CNCE JAK inhibitor for alopecia may have thinned its potential against Pfizer’s $PFE rival drugs in development.
On Monday, Concert reported the 8 mg dose of CTP-543 — its modified version of Incyte’s $INCY Jakafi — had brought about a ≥ 50% relative reduction on the Severity of Alopecia Tool (SALT) score versus placebo (p <0.001) in 47% of patients with moderate-to-severe alopecia areata at 24 weeks, thereby meeting the main goal of the Phase IIa study. Significant differences against the placebo were observed at week 12 and hair regrowth did not appear to plateau at week 24, the Lexington, Massachusetts-based company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
